Drawing for SABER

USPTO serial 97348769

SABER

Reviewed by CopyMark Law Group

Reg. 7265836Status 700Registered
Filing date
Status date
Registration date
Jan 9, 2024
Examiner
IN, SUNG HYUN
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with SABER?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Lynn E. Rzonca

Lynn E. Rzonca BALLARD SPAHR LLP1735 MARKET STREET 51ST FL.PHILADELPHIA, PA 19103UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
009Downloadable computer software for the analysis of microfluidic assays, biological assays, Tcell based assays, antigen detection assays, cell based assays, antibody assays; Microfluidic instruments, namely, chips, cartridges, droplet makers, droplet analyzers, droplet sorters, droplet imagers, droplet readers, droplet manipulators for performing microfluidics based assays, particularly biological assays, T-cell based assays, antigen detection assays, cell based assays, antibody assays, cell-cell assays, immune response assays, assays using immune cells, using blood, tumor cells, cell suspension, mammalian cell, eukaryote and procaryotes cells assays, synthetic biology assays; scientific apparatus and instruments for analyzing eukaryote and procaryotes cells, not for medical purposes, in the nature of chips, cartridges, droplet makers, droplet analyzers, droplet sorters, droplet imagers, droplet readers, droplet manipulators; scientific apparatus and instruments for analyzing single cells, not for medical purposes, in the nature of chips, cartridges, droplet makers, droplet analyzers, droplet sorters, droplet imagers, droplet readers, droplet manipulators; scientific apparatus and instruments for analyzing cells using optical components, not for medical purposes, in the nature of chips, cartridges, droplet makers, droplet analyzers, droplet sorters, droplet imagers, droplet readers, droplet manipulators; none of the foregoing relating to percutaneous transluminal angioplasty and/or cathetersACTIVE—
010Medical instruments for the purpose of detecting cancer, immune response, infectious diseases, metabolic diseases; medical devices for viewing genomes for analysis in the fields epigenomics, transcriptomics, proteomics; Cell culture apparatus for medical use, namely, cell culture reservoirs or containers; Medical apparatuses for analyzing, manipulating, or altering cells in particular human cells; none of the foregoing relating to percutaneous transluminal angioplasty and/or cathetersACTIVE—
042Research and development in the field of microorganisms and cells; scientific research services relating to the isolation and cultivation of human tissues and cells; research in the field of cell separation technology; scientific research services in the field of cell separation; Biological research; Clinical research in the field of oncology, biotechnology, epidemiology, immune-oncology, infectious disease epidemiology, metabolic disease, microbiology, immunology, genomics, epigenomics, transcriptomics; Biotechnological research; Medical research; Biological research; Bacteriological research; Medical research services; Biological research services; scientific testing in the field of biotechnology; Scientific research in the field of genetics and genetic engineering; none of the foregoing relating to percutaneous transluminal angioplasty and/or catheters; none of the foregoing in the field of agriculture and farmingACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jan 9, 2024NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Jan 9, 2024R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Oct 24, 2023NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Oct 24, 2023PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Oct 4, 2023NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Sep 18, 2023FIXDELECTRONIC RECORD REVIEW COMPLETE—
Sep 15, 2023ERRRON HOLD - ELECTRONIC RECORD REVIEW REQUIRED—
Sep 8, 2023CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Aug 29, 2023TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Aug 28, 2023CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Aug 28, 2023ERFRTEAS REQUEST FOR RECONSIDERATION RECEIVED—
Jun 13, 2023GNFNNOTIFICATION OF FINAL REFUSAL EMAILED—
Jun 13, 2023GNFRFINAL REFUSAL E-MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Jun 13, 2023CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
May 5, 2023TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
May 4, 2023CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
May 4, 2023TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Feb 8, 2023GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 8, 2023GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 8, 2023CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 24, 2023DOCKASSIGNED TO EXAMINER—
Nov 17, 2022TAEATEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED—
Nov 17, 2022PARITEAS VOLUNTARY AMENDMENT RECEIVED—
Apr 11, 2022NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Apr 9, 2022NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance